Morgan Stanley Has Lowered Expectations for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN) had its target price lowered by research analysts at Morgan Stanley from $16.00 to $15.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 31.26% from the company’s current price.

Other research analysts have also issued research reports about the stock. Barclays cut their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.60.

Organon & Co. Stock Performance

OGN opened at $11.43 on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock’s 50 day moving average price is $14.71 and its two-hundred day moving average price is $15.72. The firm has a market capitalization of $2.95 billion, a P/E ratio of 3.43, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. Organon & Co. has a 12-month low of $11.05 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Institutional Trading of Organon & Co.

Institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its stake in Organon & Co. by 238.0% during the third quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after acquiring an additional 84,136 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Organon & Co. during the 4th quarter worth about $2,263,000. Wedmont Private Capital lifted its holdings in Organon & Co. by 453.4% during the 4th quarter. Wedmont Private Capital now owns 100,539 shares of the company’s stock valued at $1,594,000 after purchasing an additional 82,372 shares during the last quarter. Sippican Capital Advisors boosted its position in Organon & Co. by 138.7% in the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company’s stock valued at $542,000 after buying an additional 21,122 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Organon & Co. by 2.0% during the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after buying an additional 82,220 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.